A unit of Johnson & Johnson said Friday that its drug Remicade received U.S. approval for a new use in children with moderate to severe ulcerative colitis.
Ulcerative colitis is a chronic inflammatory bowel disease that affects 20,000 to 40,000 children in the U.S., according to the Food and Drug Administration. Remicade is already approved as a treatment for adults with the disease.
Remicade is already FDA-approved to treat 15 other conditions including rheumatoid arthritis, plaque psoriasis and Crohn's disease.
